Peptides to Get Easier as Regulations Change

U.S. regulators recently recommended loosening restrictions on six popular peptides, potentially expanding access to substances often marketed for anti-aging and muscle recovery. The Food and Drug Administration (FDA) advisory committee voted to add these compounds to a list of substances approved for compounding pharmacies, a move that could alter the availability of these drugs through licensed medical providers.

The panel focused on six specific peptides, recommending they be added to the FDA’s 503A Bulks List. This list permits licensed compounding pharmacies to create customized medications using these substances with a valid prescription. The decision comes after the peptides were previously flagged by the FDA for safety risks and removed from a “Category 2” watchlist earlier this year to allow for further evaluation.

The six peptides recommended for inclusion include Body Protection Compound-157 (BPC-157), KPV (Lys-Pro-Val), TB-500 (Thymosin Beta-4), and MOTS-c. While the committee discussed these compounds for various uses, experts note that the evidence supporting their safety and effectiveness remains limited. “The formulation isn’t reviewed by the FDA before it reaches anyone,” says Sogol Ash, NMD, longevity director at ConciergeMD and Drip Hydration in Los Angeles. “Compounding pharmacies are overseen primarily by state boards, rather than under manufacturer-level federal oversight.”

Body Protection Compound-157 is promoted for musculoskeletal healing, though most evidence comes from animal and laboratory studies. There is a hypothetical benefit for ulcerative colitis, the committee said. KPV has early lab and animal studies suggesting skin and gut anti-inflammatory properties, while TB-500 has only a few well-designed human studies showing it could safely improve wound healing. MOTS-c is often marketed for weight loss and exercise performance, with the committee focusing on lab studies showing potential for treating obesity and osteoporosis, though human trials are limited.

Experts note that research on these peptides has been limited and inconsistent for decades.

The panel’s recommendations do not mean the FDA has approved the four peptides, nor does it make these drugs immediately available through compounding pharmacies. “The misreading I’d most want to head off is people treating this as an FDA seal of approval,” Ash says. Instead, the committee is making recommendations to the FDA about whether the peptides should be added to the agency’s 503A Bulks List.

It is important to note that a committee’s recommendation is not the same as FDA approval, and it does not mean these peptides have been proven safe or effective. “The FDA has the authority to overrule the recommendation if it deems that the evidence or public health considerations warrant a different decision,” says Rita Jew, PharmD, president at the Institute for Safe Medication Practices in San Francisco. The FDA will now review the committee’s recommendations before issuing a final decision, although the agency is not required to follow the advice of its advisory committees.

Even if the FDA adopts the recommendations, these peptides would still require a prescription and would not be sold over the counter. “Some may become more accessible, while others could become harder to obtain, depending on the FDA’s final decisions,” says Nora Khaldi, PhD, a Dublin-based molecular scientist and founder of Nuritas. Experts caution that greater access should not be mistaken for scientific validation. “A peptide becoming more widely available does not mean it has been shown to be safe and effective through the FDA drug approval process,” Khaldi says.

Experts recommend discussing any peptide therapy with a qualified healthcare provider before trying it. Patients deserve treatments supported by robust human clinical research, transparent data, and high-quality manufacturing, Khaldi adds. “That’s how we build trust in any new therapy.”